Administering naloxone: is the answer under our noses?
| dc.contributor.author | Bisset, Elspeth | |
| dc.date.accessioned | 2020-11-23T15:34:22Z | |
| dc.date.available | 2020-11-23T15:34:22Z | |
| dc.date.issued | 2009-06-01 | |
| dc.identifier.citation | Bissett, E., 2009. Administering naloxone: is the answer under our noses? Journal of Paramedic Practice, 1 (9), 359-367. | en_US |
| dc.identifier.issn | 1759-1376 | |
| dc.identifier.issn | 2041-9457 | |
| dc.identifier.doi | 10.12968/jpar.2009.1.9.42994 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12417/933 | |
| dc.description.abstract | The intranasal (IN) administration of naloxone to treat opioid overdoses offers many benefi ts over the current, often problematic intravenous and intramuscular routes. Such problems include using sharps around potentially aggressive patients; a high risk of transmitting blood-borne infections and diffi culty obtaining intravenous access in injecting drug users. A literature search was undertaken to examine the effectiveness of the IN route of naloxone administration in comparison to these other routes. Research suggests that the IN route is safe to introduce into practice and it is effective: the time taken from ambulance staff arriving at opioid overdose patients to them responding to IN naloxone appears to equal that of the intravenous route. Intranasal naloxone is not yet licensed for use in the UK and this needs to be reviewed. In the future this method of drug administration should result in considerable benefits and improved safety to both ambulance staff and patients, particularly for the treatment of opioid overdoses. Abstract published with permission | |
| dc.language.iso | en | en_US |
| dc.subject | Emergency Medical Services | en_US |
| dc.subject | Naloxone | en_US |
| dc.subject | Drug Overdose | en_US |
| dc.subject | Intranasal Drug Administration | en_US |
| dc.subject | Opioids | en_US |
| dc.title | Administering naloxone: is the answer under our noses? | en_US |
| dc.type | Journal Article/Review | |
| dc.source.journaltitle | Journal of Paramedic Practice | en_US |
| dcterms.dateAccepted | 2020-09-21 | |
| rioxxterms.version | NA | en_US |
| rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | en_US |
| rioxxterms.licenseref.startdate | 2020-09-21 | |
| refterms.panel | Unspecified | en_US |
| refterms.dateFirstOnline | 2013-09-29 | |
| html.description.abstract | The intranasal (IN) administration of naloxone to treat opioid overdoses offers many benefi ts over the current, often problematic intravenous and intramuscular routes. Such problems include using sharps around potentially aggressive patients; a high risk of transmitting blood-borne infections and diffi culty obtaining intravenous access in injecting drug users. A literature search was undertaken to examine the effectiveness of the IN route of naloxone administration in comparison to these other routes. Research suggests that the IN route is safe to introduce into practice and it is effective: the time taken from ambulance staff arriving at opioid overdose patients to them responding to IN naloxone appears to equal that of the intravenous route. Intranasal naloxone is not yet licensed for use in the UK and this needs to be reviewed. In the future this method of drug administration should result in considerable benefits and improved safety to both ambulance staff and patients, particularly for the treatment of opioid overdoses. Abstract published with permission | en_US |